Trial · NCT00445575
Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone
NCT00445575, Phase 2, Phase 3, Completed, Institut National de la Santé Et de la Recherche Médicale, France
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone. Trials, record NCT00445575. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00445575
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone
- NCT number
- NCT00445575
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 80 participants, actual
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Conditions
- Fibrous Dysplasia of Bone
- Interventions
- risedronate, placebo, risedronate, placebo
- First posted
- 2007-03-09
- Last updated
- 2021-08-30
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Intensity of bone pain, assessed by visual analogical scale ranging from 0 to 10, on the most painful site. | one year | |
| Primary | Surface of osteolytic lesions at three years. Radiological improvement. | Three years | |
| Secondary | Variation of biochemical markers of bone turnover at three years | three years | |
| Secondary | Number of painful sites | one year | |
| Secondary | Improvement in quality of life | one to three years | |
| Secondary | Variation in bone mineral density of the femoral neck at three years | three years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00445575
GET https://conductscience.org/api/trials/v1/NCT00445575/registered